Corbus Pharmaceuticals
CRBP
22 hedge funds and large institutions have $8.26M invested in Corbus Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
25% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 4
10% more funds holding
Funds holding: 20 → 22 (+2)
6% more capital invested
Capital invested by funds: $7.81M → $8.26M (+$444K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$239K |
| 2 |
SIM
Spark Investment Management
New York
|
+$141K |
| 3 |
EEG
E.E. Geduld
|
+$42.4K |
| 4 |
Renaissance Technologies
New York
|
+$40.4K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$316K |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$79K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$42K |
| 4 |
Millennium Management
New York
|
-$22.1K |
| 5 |
Morgan Stanley
New York
|
-$7.13K |
CRBP Hedge Fund Activity: Q4 2015 in Review
22 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q4 2015, worth a combined $8.26M — up 5.7% from $7.81M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CRBP positions and 2 closed out — a net gain of 2 holders — while 5 added to existing stakes and 4 trimmed.
The largest buyer was Raymond James Financial Services Advisors, opening a new position worth an estimated $239K. The largest seller was Knoll Capital Management, cutting an estimated $316K.
- 22 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q4 2015, up from 20 in Q3 2015.
- Funds reported $8.26M of Corbus Pharmaceuticals stock for Q4 2015, up 5.7% quarter-over-quarter.
- 4 funds opened new Corbus Pharmaceuticals positions in Q4 2015 and 2 closed out, a net change of +2 holders.
- The largest Corbus Pharmaceuticals buyer in Q4 2015 was Raymond James Financial Services Advisors, an estimated $239K added.
- The largest Corbus Pharmaceuticals seller in Q4 2015 was Knoll Capital Management, an estimated $316K sold.
Based on aggregated 13F filings for Q4 2015.